Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Knight

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Gut Microbiome Multi-Omics and Cognitive Function in the Hispanic Community Health Study/Study of Latinos- Investigation of Neurocognitive AgingNatalia Palacios, Scott Gordon, Tao Wang, et al.
Blood|May 28, 2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaPaul Richardson, Sundar Jagannath, Mohamad Hussein, et al.
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.
Leukemia & Lymphoma|January 15, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomideRobert M Rifkin, Rafat Abonour, Jatin J Shah, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Cancer Medicine|April 22, 2016
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomideDana E Rollison, Kenneth H Shain, Ji-Hyun Lee, et al.
Epilepsy & Behavior : E&B|November 20, 2012
Proceedings of the Third International Workshop on Advances in ElectrocorticographyAnthony Ritaccio, Michael Beauchamp, Conrado Bosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma NetworkAntonio Palumbo, Patrizia Falco, Paolo Corradini, et al.
American Journal of Hematology|November 26, 2013
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myelomaAleksandr Lazaryan, Mohamad A Hussein, Frederic J Reu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Dementia Care Research and Psychosocial FactorsDean Ornish, Catherine Madison, Miia Kivipelto, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Gut Microbiome Multi-Omics and Cognitive Function in the Hispanic Community Health Study/Study of Latinos- Investigation of Neurocognitive AgingNatalia Palacios, Scott Gordon, Tao Wang, et al.
Blood|May 28, 2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaPaul Richardson, Sundar Jagannath, Mohamad Hussein, et al.
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.
Leukemia & Lymphoma|January 15, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomideRobert M Rifkin, Rafat Abonour, Jatin J Shah, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Cancer Medicine|April 22, 2016
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomideDana E Rollison, Kenneth H Shain, Ji-Hyun Lee, et al.
Epilepsy & Behavior : E&B|November 20, 2012
Proceedings of the Third International Workshop on Advances in ElectrocorticographyAnthony Ritaccio, Michael Beauchamp, Conrado Bosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma NetworkAntonio Palumbo, Patrizia Falco, Paolo Corradini, et al.
American Journal of Hematology|November 26, 2013
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myelomaAleksandr Lazaryan, Mohamad A Hussein, Frederic J Reu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Dementia Care Research and Psychosocial FactorsDean Ornish, Catherine Madison, Miia Kivipelto, et al.
Pageof 7